Background
In my last article, I have already reviewed BioMarin's (NASDAQ:BMRN) business. Since then, some news was released. Now, I would like to revise my forecast. I would also like to analyze in detail the option with
BioMarin: More Opportunities Ahead
Summary
- The value of the current BioMarin's business + Voxzogo is $104 per share.
- Total BioMarin's value per share based on the DCF model is $126.
- BioMarin could become an acquisition target. The possible buyers are Sanofi, Roche, and Vertex.
I am the head of research for the pre-IPO and venture division of the investment bank. Prior to that, I have been working as a global equity research analyst in an investment bank for the past 5 years. My specialization are Biotechnology, Internet and Media. I Received my CFA Charter in 2017. Also, I am FRM Charter. Besides, I am the author of the Russian-language Telegram-channel (the link in the section Website URL).
Analyst’s Disclosure:I/we have a beneficial long position in the shares of BMRN, VRTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This is not investment advice. I am not an investment adviser. Before making any investment, please do your own research!
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.